Femasys Inc.
- FEMY
- NASDAQ
- Medical - Instruments & Supplies
- Women's Health/Contraceptives
- Medical Devices (Reproductive)
- Fertility
$1.66
Today −0.60%Quote Oct 21, 2026, 03:09 PM UTC
−33.99%over the last month
Max drawdown −39.5%From 1-month high −35.3%3 months −52.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Overview
About Femasys
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering.
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Exchange
NASDAQ
Employees
53
Market value
$13.9M
Quote Oct 21
Floor
$1.46
12.0% below price
Resistance
$1.71
3.0% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about FEMYPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeGo deeper
The case
Verdict, why now, and the write-up open with Pro.
Log in — 14 days freeFundamentals
Fundamentals
-197.9%
How much profit the company makes on the money in the business.
What the business earns on its capital.
P/E
Not shown
Trailing earnings are negative, so this ratio has no meaning. Price to sales is shown instead.
ROIC
-197.9%
Low
Higher than 0% of companies in Medical - Instruments & Supplies
D/E
1.19
Leverage · High debt
Higher than 88% of companies in Medical - Instruments & Supplies
Price to sales
6.34xIn the middle
PEG
Not shown
Trailing earnings are negative, so this ratio has no meaning. Price to sales is shown instead.
P/B
1.45xIn the middle
ROA
-100.0%Low
Financials
Financials
-18.9%
Sales fell from a year ago.
Latest quarter sales were $331,827.
- Revenue
- Net Income
- Net margin
Q2 2026
$332K-18.9%
Revenue
$331,827
Vs year ago
-18.9%
TTM net margin
-419.7%
Net Income
$-4.5M
Technical
Technical
3.0%
Price often stalls there.
Below where sellers stopped the price last time.
Direction
Going down
Heat
Cooling off
Crowd activity
Buyers in charge
52-week
$1.56$1.66$20.80
12-week
$1.46$1.66$3.69
News
Verdict, why now, and the write-up open with Pro.
Log in — 14 days free